Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I trial of oxyfedrine plus sulfasalazine in unresectable recurrent solid tumors (FC001-TR)
jRCT1030230529Phase 1Active, not recruiting
- Sponsor
- NA
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxyfedrine and 5-aminosalicylic acid + sulphasalazine in Nonhematologic neoplasms, sponsored by NA. Primary endpoint: Correlation of objective response rate or disease control rate with biomarkers. Started Dec 2023; status: active, not recruiting.
02
Drugs
oxyfedrine5-aminosalicylic acid + sulphasalazine
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT1030230529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1030230529.